Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
5/28/2026, 12:00:00 AM
The World Health Organization (WHO) endorsed maftivimab, a component of Regeneron's Ebola treatment Inmazeb, for prioritization in clinical trials against the Bundibugyo ebolavirus strain.
Korean Translation
세계보건기구(WHO)가 리제네론의 에볼라 치료제 인마제브의 구성 요소인 마프티비맙을 분디부교 에볼라 바이러스 균주에 대한 임상시험 우선순위 대상으로 지정함.
Related Recent Events
Cisco Systems Inc (CSCO) · Earnings Release
Cisco's Q4 and full fiscal year 2026 earnings release scheduled for August 12, 2026, is assigned high importance due to an estimated price impact of over 10%, scheduled.
8/12/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Gilead's Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
The Q2 2026 earnings release for Rocket Lab is set for August 6, 2026, scheduled.
8/6/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release scheduled for August 4, 2026. Analysts project an EPS of $1.55 estimated. Medium importance reflects typical volatility around earnings releases.
8/4/2026, 12:00:00 AM
Monolithic Power Systems Inc (MPWR) · Earnings Release
Monolithic Power Systems Q2 2026 earnings release on 2026-07-30 with analysts forecast of $5.85 EPS forecasted. High importance expected due to historical price volatility during earnings expected.
7/30/2026, 12:00:00 AM
QUALCOMM Inc. (QCOM) · Earnings Release
Qualcomm is expected to release its fiscal Q3 2026 earnings results on July 29, 2026, expected.
7/29/2026, 12:00:00 AM